Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01332292 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT01332292 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 27 participants.
The verdict
NCT01332292, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study will investigate the effect of dosing with flutucasone furoate in asthmatic subjects aged 5-11 years of age. A randomized, two-way crossover, with placebo control, over a 14 day treatment period, it will investigate safety, tolerability, pharmacokinetics and serum cortisol levels.
Interventions
- DRUG Matching placebo
- DRUG Fluticasone furoate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01332292
The ClinicalTrials.gov registry entry for NCT01332292 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching placebo is the first listed.
NCT01332292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01332292 about?
NCT01332292 is a clinical study titled "Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients". This study will investigate the effect of dosing with flutucasone furoate in asthmatic subjects aged 5-11 years of age. A randomized, two-way crossover, with placebo control, over a 14 day treatment period, it will investigate safety, tolerability, pharmacokinetics and serum cortisol levels.
What is the current status of trial NCT01332292?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2010-05. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01332292?
The interventions under investigation include: Matching placebo (DRUG), Fluticasone furoate (DRUG).
Who is sponsoring clinical trial NCT01332292?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.